, Volume 6, Issue 1, pp 106–118

Transforming the critique of Big Pharma

  • Anne Pollock
Original Article


Intersecting fields of scholarship have accounted for pharmaceutical companies’ extraordinary success in promoting and profiting from their wares. This article instead tracks resistances and failures in the terrain of Big Pharma amid economic, epistemological and political challenges to their business models. Pfizer has been a key player in the rise of Big Pharma, and its fortunes since 2006 provide windows into the industry's stagnation – the failure of Pfizer's would-be blockbuster torcetrapib, the closing of its heart disease research unit, its free drug program for newly unemployed Americans. These illustrate transformations in ‘least neglected diseases’ and in pricing structures, and can be understood in the contexts of both biotech and Global South critique. Biotech companies have remained profitable by creating biologics for niche subsets of rich populations with a high willingness to pay (including lucrative treatments I call ‘drugs for short lives’). At the same time, dominant global capitalists/philanthropists have brought unprecedented funding to making treatment for AIDS and TB available to the poor and tackling long-neglected diseases like malaria. Now that pharmaceutical profits and markets seem less than infinite in their expansion and philanthropy has been pharmaceuticalized, the stakes of demands like ‘medicine for people not for profit’ are changing. STS critique of pharmaceuticals should take these transformations into account as it deepens its systemic critique of global inequality.


pharmaceuticals Pfizer blockbuster drugs heart disease financial crisis philanthropy 


  1. Alazraki, M. (2009) Pfizer Earnings Beat the Street. Beating Future Hurdles Will be Harder. Daily Finance, 20 October,, accessed 21 October 2009.
  2. Angell, M. (2004) The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York: Random House.Google Scholar
  3. Armstrong, W. (2009) Attack of the monster merger: What the Wyeth deal means for Pfizer – And the rest of pharma. Pharmaceutical Executive 29 (3): 36–48.Google Scholar
  4. Barter, P.J. et al (2007) Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine 357 (21): 2109–2122.CrossRefGoogle Scholar
  5. Berenson, A. (2005) Pfizer stirs concern with plans to sell heart drugs only as a pair. New York Times, 7 March.Google Scholar
  6. Berenson, A. (2006) Pfizer ends its studies on drug for heart disease. New York Times.Google Scholar
  7. Biehl, J. (2007) Pharmaceuticalization: AIDS treatment and global health politics. Anthropological Quarterly 80 (4): 1083–1126.CrossRefGoogle Scholar
  8. Bill and Melinda Gates Foundation. (2009) Global health program fact sheet,
  9. Chomsky, N. (2001) 9–11. New York: Seven Stories Press.Google Scholar
  10. Clarke, A., Shim, J.K., Mamo, L., Fosket, J.R. and Fishman, J.R. (2003) Biomedicalization: Transformations in health, illness, and U.S. biomedicine. American Sociological Review 68 (2): 161–194.CrossRefGoogle Scholar
  11. Clinton Health Access Initiative. (2010) What we do,
  12. Congressional Budget Office. (2006) A CBO study: Research and development in the pharmaceutical industry,
  13. Cooper, M. (2006) Resuscitations: Stem cells and the crisis of old age. Body and Society 12 (1): 1–23.CrossRefGoogle Scholar
  14. Cooper, M. (2008) Life As Surplus: Biotechnology and Capitalism in the Neo-Liberal Era. Seattle, WA: University of Washington Press.Google Scholar
  15. Das, V. and Das, R.K. (2006) Pharmaceutical in urban ecologies: The register of the local. In: A. Petryna, A. Lakoff and A. Kleinman (eds.) Global Pharmaceuticals: Ethics, Markets, Practices. Durham, NC: Duke University Press, pp. 171–205.Google Scholar
  16. Derrida, J. (1981) Plato's Pharmacy. In: Dissemination, Translated by B. Johnson. Chicago, IL: University of Chicago Press, pp. 61–171.Google Scholar
  17. Dumit, J. (2002) Drugs for life. Molecular Interventions 2 (3): 124–127.CrossRefGoogle Scholar
  18. Dumit, J. (forthcoming) Drugs for Life: Managing Health and Identity through Facts and Pharmaceuticals. Durham, NC: Duke University Press.Google Scholar
  19. Ecks, S. (2005) Pharmaceutical citizenship: Antidepressant marketing and the promise of demarginalization in India. Anthropology & Medicine 12 (3): 239–254.CrossRefGoogle Scholar
  20. Ecks, S. (2008) Global pharmaceutical markets and corporate citizenship: The case of Novartis’ Anti-Cancer Drug Glivec. BioSocieties 3 (2): 165–181.CrossRefGoogle Scholar
  21. Ewart, R. (2008) Lessons from Torcetrapib: Putting patient-oriented medicine first. American Family Physician 77 (5, March): 597–598.Google Scholar
  22. Garber, A.M. (2009) An uncertain future for cardiovascular drug development? New England Journal of Medicine 360 (12, March): 1169.CrossRefGoogle Scholar
  23. Gertner, A. (2010) Science of uncertainty: Making cases for drug incorporation in Brazil. Anthropological Quarterly 83 (1): 97–112.CrossRefGoogle Scholar
  24. Greene, J. (2008) Prescribing by Numbers: Drugs and the Definition of Disease. Baltimore, MD: Johns Hopkins University Press.Google Scholar
  25. Haraway, D. (1991) A cyborg manifesto: Science, technology, and socialist-feminism in the late twentieth century. In: Simians, Cyborgs and Women: The Reinvention of Nature. New York: Routledge, pp. 149–181.Google Scholar
  26. Harris, G. (2009) Pfizer pays 2.3 billion to settle marketing case. New York Times, p. B4, September.Google Scholar
  27. Hayden, C. (2007) A generic solution? Pharmaceuticals and the politics of the similar in Mexico. Current Anthropology 48 (4): 475–495.CrossRefGoogle Scholar
  28. Hirschler, B. (2010) Data shows declining productivity in drug R&D. Reuters, June,
  29. Jackson, E. (2010) Top-up payments for expensive cancer drugs: Rationing, fairness and the NHS. Modern Law Review 73 (3): 399–427.CrossRefGoogle Scholar
  30. Kahn, J. (2008) Exploiting race in drug development: BiDil's interim model of pharmacogenomics. Social Studies of Science 38 (5): 737–758.CrossRefGoogle Scholar
  31. Kahn, J. and Sankar, K. (2005) BiDil: Race medicine or race marketing? Health Affairs 24: 455–463.CrossRefGoogle Scholar
  32. Klug, H. (2008) Law, politics, and access to essential medicines in developing countries. Politics & Society 36 (2): 207–246.CrossRefGoogle Scholar
  33. Krumholz, H.M. and Lee, T.H. (2008) Redefining quality – Implications of recent clinical trials. New England Journal of Medicine 358 (24): 2537.CrossRefGoogle Scholar
  34. Lacey, M. (2005) Look at the place!: Sudan says, “say sorry,” but the U.S. won’t. New York Times.Google Scholar
  35. Lakoff, A. (2007) The right patients for the drug: Managing the placebo effect. Biosocieties 2: 57–73.CrossRefGoogle Scholar
  36. Mamo, L. and Fishman, J.R. (2001) Potency in all the right places: Viagra as a technology of the gendered body. Body and Society 7: 13–35.CrossRefGoogle Scholar
  37. Marres, N. and McGoey, L. (2010) Experimental failure. Presented at After Markets, Oxford University.Google Scholar
  38. Martinez, B. and Goldstein, J. (2007) Big pharma faces grim prognosis: Industry fails to find new drugs to replace wonders like lipitor. Wall Street Journal,
  39. McGoey, L. (2010) Profitable failure: Antidepressant drugs and the triumph of flawed experiments. History of the Human Sciences 23 (1): 58–78.CrossRefGoogle Scholar
  40. New York Times. (2005) A troubling drug combination. 2 March.Google Scholar
  41. New York Times. (2008) Pfizer to focus on more profitable diseases. 30 September.Google Scholar
  42. Nguyen, V-K. (2005) Anti-retroviral globalism, biopolitics, and therapeutic citizenship. In: A. Ong and S. Collier (eds.) Global Assemblages: Technology, Politics, and Ethics as Anthropological Problems. Malden, MA: Blackwell, pp. 124–144.Google Scholar
  43. Novas, C. (2007) Patients, profits, and values: Myozyme as an exemplar of biosociality. In: S. Gibbon and C. Novas (eds.) Biosocialities, Genetics, and the Social Sciences: Making Biologies and Identities. London: Routledge, pp. 136–156.Google Scholar
  44. Persson, A. (2004) Incorporating pharmakon: HIV, medicine, and body shape change. Body and Society 10 (4): 45–67.CrossRefGoogle Scholar
  45. Petrecca, L. (2009) Pfizer offers free drugs, Lipitor, Viagra, to unemployed. USA Today, 14 May.Google Scholar
  46. Petryna, A. (2009) When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton, NJ: Princeton University Press.CrossRefGoogle Scholar
  47. Pfizer. (2007) Pfizer announces launch of generic amlodipine besylate product by greenstone., accessed 23 March.
  48. Pfizer. (2008) Information about the MAINTAIN™ program: A free medicines program for newly unemployed Americans.
  49. Pfizer. (2009) President Clinton, Pfizer, and Mylan announce new agreements to lower prices of medicines for patients with drug-resistant HIV in developing countries,
  50. Pollack, A. (2009) Forty years war: Taking big risk for big payoff, industry seeks cancer drugs. New York Times, 2 September.Google Scholar
  51. Pollock, A. (2008) Pharmaceutical meaning-making beyond marketing: The racialized subjects of generic thiazide. Journal of Law, Medicine and Ethics 36 (3): 530–536.CrossRefGoogle Scholar
  52. Pollock, A. (forthcoming) Medicating Race: Heart Disease and Durable Preoccupations with Difference. Durham, NC: Duke University Press.Google Scholar
  53. Rasmussen, N. (2008) On Speed: The Many Lives of Amphetamine. New York: New York University Press.Google Scholar
  54. Reagan, R. (1961) Ronald Reagan Speaks Out Against Socialized Medicine, LP Record. Chicago, IL: American Medical Association.Google Scholar
  55. Risen, J. (1999) To bomb Sudan Plant, or not: a year later, debates rankle. New York Times, 27 October.Google Scholar
  56. Rose, N. (2006) The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century. Princeton, NJ: Princeton University Press.Google Scholar
  57. Saul, S. (2008) In sour economy, some scale back on medications. New York Times, 30 September.Google Scholar
  58. Sismondo, S. (2008) How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Social Science & Medicine Volume 66 (9): 1909–1914.CrossRefGoogle Scholar
  59. Universities Allied for Essential Medicines. (2009) Global access licensing framework. February,
  60. Wang, S.S. and Lublin, J.S. (2008) Pfizer plans to abandon heart-drug development. The Wall Street Journal, 30 September.Google Scholar
  61. Van, Der Geest S., White, S.R. and Hardon, A. (1996) The anthropology of pharmaceuticals: A biographical approach. Annual Review of Anthropology 25: 153–178.CrossRefGoogle Scholar
  62. Zizek, S. (2009) First as Tragedy, Then as Farce. London and Brooklyn, NY: Verso Books.Google Scholar

Copyright information

© The London School of Economics and Political Science 2011

Authors and Affiliations

  • Anne Pollock
    • 1
  1. 1.Georgia Tech School of Literature, Communication and CultureAtlantaUSA

Personalised recommendations